-
The National Medical Journal of India 2019Premenstrual syndrome (PMS) refers to a set of distressing symptoms experienced around the time of menstrual flow. Hormonal changes may underlie these symptoms which can...
BACKGROUND
Premenstrual syndrome (PMS) refers to a set of distressing symptoms experienced around the time of menstrual flow. Hormonal changes may underlie these symptoms which can lead to difficulties in day-to-day functioning and poor quality of life.
METHODS
In this cross-sectional study, 300 students attending the science stream at a women's college of Puducherry were administered self-reported questionnaires to obtain socio- demographic, dietary, lifestyle and family details. The Shortened Premenstrual Assessment Form was used to assess PMS, a symptom checklist was used to assess premenstrual dysphoric disorder and Short From 36 was used to assess quality of life.
RESULTS
The prevalence of PMS was 62.7%. Back, joint and muscle aches were the most common symptoms followed by abdominal heaviness and discomfort. PMS was associated with a poorer quality of life across all domains. About half the students had affective symptoms in the premenstrual phase.
CONCLUSION
Dietary and lifestyle factors such as consumption of sweets and lack of physical activity were associated with the presence of PMS.
Topics: Adolescent; Adult; Affective Symptoms; Cross-Sectional Studies; Exercise; Feeding Behavior; Female; Humans; India; Life Style; Premenstrual Syndrome; Prevalence; Quality of Life; Risk Factors; Students; Universities; Young Adult
PubMed: 31823933
DOI: 10.4103/0970-258X.272109 -
Nutrients Aug 2019Premenstrual syndrome (PMS) is a cyclical late luteal phase disorder of the menstrual cycle whereby the daily functioning of women is affected by emotional and physical...
Premenstrual syndrome (PMS) is a cyclical late luteal phase disorder of the menstrual cycle whereby the daily functioning of women is affected by emotional and physical symptoms substantially interfering with their quality of life. Little is known about PMS in the United Arab Emirates (UAE). This study aimed to determine the prevalence and severity of PMS among university students in Sharjah, UAE, and clarify its associations with dietary habits, lifestyle behaviors, and anthropometric factors. A cross-sectional study was conducted on female college students at the University of Sharjah, UAE. Data were collected using self-administered questionnaires and anthropometric assessments. Descriptive statistics and multiple logistic regression analyses were performed. Participants were 300 adult university students aged 18-24 years (mean age 20.07 ± 1.53 years). In total, 95% of participants reported at least one PMS symptom during their menstrual period. The prevalence of PMS was 35.3%, with mild symptoms being the most commonly reported. Multiple regression analysis showed that smoking was associated with increased risk of reporting psychological (OR 2.5, 95% CI 1.1-5.8; < 0.05) and behavioral symptoms (OR 2.2, 95% CI 1.0-4.9; < 0.05), while high calorie/fat/sugar/salt foods intake was associated with increased risk of reporting physical symptoms (OR 3.2, 95% CI 1.4-7.3; < 0.05). However, fruit consumption (OR 0.34, 95% CI 0.125-0.92; < 0.05) was associated with a decreased risk of reporting behavioral symptoms. A high prevalence of PMS was reported among university students, with smoking and high calorie/fat/sugar/salt food consumption identified as strong risk factors for PMS.
Topics: Adult; Cross-Sectional Studies; Diet; Emotions; Energy Intake; Feeding Behavior; Female; Humans; Life Style; Logistic Models; Premenstrual Syndrome; Prevalence; Quality of Life; Risk Factors; Severity of Illness Index; Smoking; Students; Surveys and Questionnaires; United Arab Emirates; Universities; Young Adult
PubMed: 31426498
DOI: 10.3390/nu11081939 -
The British Journal of Psychiatry : the... Oct 2022Evidence on risk factors for postpartum depression (PPD) are fragmented and inconsistent. (Review)
Review
BACKGROUND
Evidence on risk factors for postpartum depression (PPD) are fragmented and inconsistent.
AIMS
To assess the strength and credibility of evidence on risk factors of PPD, ranking them based on the umbrella review methodology.
METHOD
Databases were searched until 1 December 2020, for systematic reviews and meta-analyses of observational studies. Two reviewers assessed quality, credibility of associations according to umbrella review criteria (URC) and evidence certainty according to Grading of Recommendations-Assessment-Development-Evaluations criteria.
RESULTS
Including 185 observational studies ( = 3 272 093) from 11 systematic reviews, the association between premenstrual syndrome and PPD was the strongest (highly suggestive: odds ratio 2.20, 95%CI 1.81-2.68), followed by violent experiences (highly suggestive: odds ratio (OR) = 2.07, 95%CI 1.70-2.50) and unintended pregnancy (highly suggestive: OR=1.53, 95%CI 1.35-1.75). Following URC, the association was suggestive for Caesarean section (OR = 1.29, 95%CI 1.17-1.43), gestational diabetes (OR = 1.60, 95%CI 1.25-2.06) and 5-HTTPRL polymorphism (OR = 0.70, 95%CI 0.57-0.86); and weak for preterm delivery (OR = 2.12, 95%CI 1.43-3.14), anaemia during pregnancy (OR = 1.47, 95%CI 1.17-1.84), vitamin D deficiency (OR = 3.67, 95%CI 1.72-7.85) and postpartum anaemia (OR = 1.75, 95%CI 1.18-2.60). No significant associations were found for medically assisted conception and intra-labour epidural analgesia. No association was rated as 'convincing evidence'. According to GRADE, the certainty of the evidence was low for Caesarean section, preterm delivery, 5-HTTLPR polymorphism and anaemia during pregnancy, and 'very low' for remaining factors.
CONCLUSIONS
The most robust risk factors of PDD were premenstrual syndrome, violent experiences and unintended pregnancy. These results should be integrated in clinical algorithms to assess the risk of PPD.
Topics: Cesarean Section; Depression; Depression, Postpartum; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Premenstrual Syndrome; Risk Factors; Systematic Reviews as Topic
PubMed: 35081993
DOI: 10.1192/bjp.2021.222 -
BMJ Clinical Evidence Aug 2015A woman has premenstrual syndrome (PMS) if she complains of recurrent psychological and/or physical symptoms occurring during the luteal phase of the menstrual cycle,... (Review)
Review
INTRODUCTION
A woman has premenstrual syndrome (PMS) if she complains of recurrent psychological and/or physical symptoms occurring during the luteal phase of the menstrual cycle, and often resolving by the end of menstruation. Symptom severity can vary between women. Premenstrual symptoms occur in 95% of women of reproductive age. Severe, debilitating symptoms occur in about 5% of those women. There is no consensus on how symptom severity should be assessed for PMS, which has led to the use of a wide variety of symptom scores and scales, thus making it difficult to synthesise data on treatment efficacy. The cyclical nature of the condition also makes it difficult to conduct RCTs.
METHODS AND OUTCOMES
We conducted a systematic overview, aiming to answer the following clinical question: What are the effects of continuous hormonal treatments in women with premenstrual syndrome? We searched: Medline, Embase, The Cochrane Library, and other important databases up to April 2014 (Clinical Evidence overviews are updated periodically; please check our website for the most up-to-date version of this overview).
RESULTS
At this update, searching of electronic databases retrieved 132 studies. After deduplication and removal of conference abstracts, 132 records were screened for inclusion in the overview. Appraisal of titles and abstracts led to the exclusion of 102 studies and the further review of 30 full publications. Of the 30 full articles evaluated, one systematic review and three RCTs were added to this overview. We performed a GRADE evaluation for three PICO combinations.
CONCLUSIONS
In this systematic overview, we categorised the efficacy for three interventions based on information relating to the effectiveness and safety of continuous combined oral contraceptives, continuous transdermal estradiol, and continuous subcutaneous estradiol implants.
Topics: Administration, Cutaneous; Contraceptives, Oral, Combined; Drug Implants; Estradiol; Female; Humans; Infusions, Subcutaneous; Premenstrual Syndrome
PubMed: 26303988
DOI: No ID Found -
BMC Complementary Medicine and Therapies Jan 2022Vitamin D has an established role in female reproduction. There is also evidence for an association between vitamin D levels and menstrual problems such as premenstrual... (Randomized Controlled Trial)
Randomized Controlled Trial
BACKGROUND
Vitamin D has an established role in female reproduction. There is also evidence for an association between vitamin D levels and menstrual problems such as premenstrual syndrome (PMS) and dysmenorrhea. Curcumin, is a bioactive polyphenol constituent of turmeric, that can potentially interact with vitamin D receptors and its molecular targets. This study evaluated the effects of curcumin on vitamin D levels in young women with PMS and dysmenorrhea.
METHODS
In this randomized, triple-blind, placebo-controlled trial, women with PMS and dysmenorrhea were divided randomly into experimental and control groups to receive one capsule (500 mg of curcuminoid+ 5 mg piperine, or placebo) daily, from approximately 7 days before until 3 days after menstruation for three consecutive menstrual cycles. Serum vitamin D levels, renal function, and liver enzymes were also measured before and after intervention.
RESULTS
A total of 76 subjects (38 in each group) were recruited into the trial. Curcumin significantly increased the median (IQR) serum levels of vitamin D [from 12.8 ng/ml (7.0-24.6) to 16.2 ng/ml (6.4-28.8); P = 0.045], compared with placebo [from 18.6 ng/ml (2.2-26.8) to 21.3 ng/ml (5.2-27.1); P = 0.17]. Serum levels of aspartate aminotransferase and direct bilirubin were reduced by the end of trial in the curcumin group (p < 0.05), but did not change significantly in the control group (p > 0.05). Finally, no significant differences in levels of fasting blood glucose were detected between curcumin and placebo groups.
CONCLUSION
Curcumin supplementation in women with PMS and dysmenorrhea led to a significant improvement of vitamin D, liver function enzyme test, but did not affect blood glucose.
TRIAL REGISTRATION
The trial was registered on Iranian Registry of Clinical Trials registry (Trial ID: IRCT20191112045424N1 on 23 January 2020; available at https://www.irct.ir ).
Topics: Aspartate Aminotransferases; Bilirubin; Curcumin; Dietary Supplements; Dysmenorrhea; Female; Humans; Premenstrual Syndrome; Research Design; Vitamin D; Young Adult
PubMed: 35065636
DOI: 10.1186/s12906-022-03515-2 -
BMC Women's Health May 2018Premenstrual syndrome (PMS) is a common disorder among women of reproductive age. Nearly 40% of women report problems with their menstrual cycles. Exercise is one of the... (Comparative Study)
Comparative Study Randomized Controlled Trial
BACKGROUND
Premenstrual syndrome (PMS) is a common disorder among women of reproductive age. Nearly 40% of women report problems with their menstrual cycles. Exercise is one of the recommended treatments to reduce symptoms of premenstrual syndrome (PMS). The present study was conducted to determine the effect of 8 weeks aerobic exercise on severity of physical symptoms of premenstrual syndrome (PMS).
METHODS
This study was a randomized clinical trial (IRCT2015021721116N1) that was performed on 65 students living in student dormitories of Mashhad University of Medical Sciences in 2016, Iran. Samples were randomly assigned to control and intervention groups. The intervention group engaged in 8 weeks of aerobic exercises, three times a week, and 20 min for each session. The tools were research unit selection questionnaire, midwifery and personal particulars, temporary determination of premenstrual syndrome, Beck Depression, recorded daily symptoms of premenstrual syndrome and Borg scale. We analyzed the data using SPSS software and Mann-Whitney U test and Friedman test.
RESULTS
At the beginning of the study, both control and intervention groups were homogeneous. The results of independent t-test showed that among the physical symptoms of the premenstrual syndrome in the intervention group compared to the control group, at the end of the study, headache (p = 0.001), nausea, constipation diarrhea (p = 0.01), swollen (p = 0/001) had a significant reduction. Also, the comparison of the difference between the mean of the signs at the beginning and the end of the study, bloating (p = 0.01), Vomiting (p = 0.002), hot flashes (p = 0.04), increase in appetite (p = 0.008) were significantly decreased.
CONCLUSION
Aerobic exercise as one of the ways to treat premenstrual syndrome can reduce the physical symptoms of the syndrome.
TRIAL REGISTRATION
Name of registry: Zahra Mohebbi Dehnavi. IRCT registration number: IRCT 2015021721116 N1. Registration date: 2015 - 08-28. Registration timing: retrospective.
Topics: Adult; Exercise; Female; Humans; Iran; Menstrual Cycle; Premenstrual Syndrome; Retrospective Studies; Students; Surveys and Questionnaires; Universities; Young Adult
PubMed: 29855308
DOI: 10.1186/s12905-018-0565-5 -
Frontiers in Endocrinology 2023Vitex agnus castus (VAC), also known as chaste tree, is a plant from the Mediterranean area, Crimea, and central Asia. Its fruit has been used for more than 2500 years... (Review)
Review
BACKGROUND
Vitex agnus castus (VAC), also known as chaste tree, is a plant from the Mediterranean area, Crimea, and central Asia. Its fruit has been used for more than 2500 years as phytotherapic agent. In the last century, VAC has been mostly used for the treatment of premenstrual syndrome (PMS), menstrual irregularities, fertility disorders, and symptoms of menopause. Since some degree of hyperprolactinaemia may be observed in patients with such disorders, VAC effects on hyperprolactinaemia have been assessed in a small number of studies and in some patient series or single case reports. It has been postulated that the diterpenes contained in VAC extract may interact with dopamine D2 receptors (D2R) and inhibit prolactin release via dopamine D2R activation in the anterior pituitary. Most of the published papers focus on the use of VAC for the management of PMS or infertility. However, due to its action on D2R, VAC could have a role in the treatment of mild hyperprolactinaemia, including patients with idiopathic hyperprolactinaemia, microprolactinoma, drug-induced hyperprolactinaemia, or polycystic ovary syndrome.
METHODS
We have reviewed and analysed the data from the literature concerning the use of VAC extracts in patients with hyperprolactinaemia.
RESULTS
Some evidence suggests a possible role of VAC for the management of hyperprolactinaemia in selected patients, though in an inhomogeneous way. However, there are not any large randomized controlled trials supporting the same and the precise pharmacological aspects of VAC extract in such a clinical setting still remain obscure.
CONCLUSION
It appears that VAC may represent a potentially useful and safe phytotherapic option for the management of selected patients with mild hyperprolactinaemia who wish to be treated with phytotherapy. However, larger studies of high quality are needed to corroborate it.
Topics: Female; Humans; Hyperprolactinemia; Plant Extracts; Vitex; Phytotherapy; Premenstrual Syndrome; Pituitary Neoplasms
PubMed: 38075075
DOI: 10.3389/fendo.2023.1269781 -
The Cochrane Database of Systematic... Jun 2023Premenstrual syndrome (PMS) is a common problem. Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome. Combined oral contraceptives (COC),... (Review)
Review
BACKGROUND
Premenstrual syndrome (PMS) is a common problem. Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome. Combined oral contraceptives (COC), which provide both progestin and oestrogen, have been examined for their ability to relieve premenstrual symptoms. A combined oral contraceptive containing drospirenone and a low oestrogen dose has been approved for treating PMDD in women who choose combined oral contraceptives for contraception.
OBJECTIVES
To evaluate the effectiveness and safety of COCs containing drospirenone in women with PMS.
SEARCH METHODS
We searched the Cochrane Gynaecology and Fertility Group trial register, CENTRAL (now containing output from two trials registers and CINAHL), MEDLINE, Embase, PsycINFO, LILACS, Google Scholar, and Epistemonikos on 29 June 2022. We checked included studies' reference lists and contacted study authors and experts in the field to identify additional studies.
SELECTION CRITERIA
We included randomised controlled trials (RCT) that compared COCs containing drospirenone with placebo or with another COC for treatment of women with PMS.
DATA COLLECTION AND ANALYSIS
We used standard methodological procedures recommended by Cochrane. The primary review outcomes were effects on premenstrual symptoms that were prospectively recorded, and withdrawal due to adverse events. Secondary outcomes included effects on mood, adverse events, and response rate to study medications.
MAIN RESULTS
We included five RCTs (858 women analysed, most diagnosed with PMDD). The evidence was very low to moderate quality; the main limitations were serious risk of bias due to poor reporting of study methods, and serious inconsistency and imprecision. COCs containing drospirenone and ethinylestradiol (EE) versus placebo COCs containing drospirenone and EE may improve overall premenstrual symptoms (standardised mean difference (SMD) -0.41, 95% confidence interval (CI) -0.59 to -0.24; 2 RCTs, N = 514; I = 64%; low-quality evidence); and functional impairment due to premenstrual symptoms in terms of productivity (mean difference (MD) -0.31, 95% CI -0.55 to -0.08; 2 RCTs, N = 432; I = 47%; low-quality evidence), social activities (MD -0.29, 95% CI -0.54 to -0.04; 2 RCTs, N = 432; I = 53%; low-quality evidence), and relationships (MD -0.30, 95% CI -0.54 to -0.06; 2 RCTs, N = 432; I = 45%; low-quality evidence). The effects from COCs containing drospirenone may be small to moderate. COCs containing drospirenone and EE may increase withdrawal from trials due to adverse effects (odds ratio (OR) 3.41, 95% CI 2.01 to 5.78; 4 RCT, N = 776; I = 0%; low-quality evidence). This suggests that if you assume the risk of withdrawal due to adverse effects from placebo is 3%, the risk from drospirenone plus EE will be between 6% and 16%. We are uncertain of the effect of drospirenone plus EE on premenstrual mood symptoms, when measured by validated tools that were not developed to assess premenstrual symptoms. COCs containing drospirenone may lead to more adverse effects in total (OR 2.31, 95% CI 1.71 to 3.11; 3 RCT, N = 739; I = 0%; low-quality evidence). This suggests that if you assume the risk of having adverse effects from placebo is 28%, the risk from drospirenone plus EE will be between 40% and 54%. It probably leads to more breast pain, and may lead to more nausea, intermenstrual bleeding, and menstrual disorder. Its effect on nervousness, headache, asthenia, and pain is uncertain. There was no report of any rare but serious adverse effects, such as venous thromboembolism in any of the included studies. COCs containing drospirenone may improve response rate (OR 1.65, 95% CI 1.13 to 2.40; 1 RCT, N = 449; I not applicable; low-quality evidence). This suggests that if you assume the response rate from placebo is 36%, the risk from drospirenone plus EE will be between 39% and 58%. We did not identify any studies that compared COCs containing drospirenone with other COCs.
AUTHORS' CONCLUSIONS
COCs containing drospirenone and EE may improve premenstrual symptoms that result in functional impairments in women with PMDD. The placebo also had a significant effect. COCs containing drospirenone and EE may lead to more adverse effects compared to placebo. We do not know whether it works after three cycles, helps women with less severe symptoms, or is better than other combined oral contraceptives that contain a different progestogen.
Topics: Female; Humans; Contraceptives, Oral, Combined; Drug-Related Side Effects and Adverse Reactions; Estrogens; Premenstrual Dysphoric Disorder; Premenstrual Syndrome; Progestins
PubMed: 37365881
DOI: 10.1002/14651858.CD006586.pub5 -
Journal of the Turkish German... Jun 2024Premenstrual syndrome (PMS) is a common condition among women during their menstrual cycle. PMS can negatively affect a woman's daily life and function. Nurses, as an...
OBJECTIVE
Premenstrual syndrome (PMS) is a common condition among women during their menstrual cycle. PMS can negatively affect a woman's daily life and function. Nurses, as an important and substantial segment of healthcare staff, are affected by the demanding environment of work place. Since PMS, as a prevalent counterproductive condition, has not been studied in this population in Iran, we assessed the prevalence of PMS and its associated factors among nurses aged 23 to 49 in teaching hospitals of the Tehran province of Iran.
MATERIAL AND METHODS
In this cross-sectional study from April 2021 to January 2022, 280 participants from teaching hospitals were enrolled. Simple random sampling was used to determine the sample size of the study. Two validated questionnaires and a data gathering sheet were used to collect information. The premenstrual symptoms screening tool was used to determine PMS severity and the Copenhagen Psychosocial Questionnaire to evaluate the associated job demands. Demographic data and work-related data included: night shift, shift type, monthly COVID-19 care and gynecologic and past medical history were gathered. Then data were analyzed using logistic regression analysis, chi-square and t-test.
RESULTS
The severity of PMS was: mild (42.5%); moderate (30%); and severe (27.5%). Regular menstruation and dysmenorrhea were reported by 84.6% and 72.3%, respectively. Moderate to severe PMS was associated with: monthly COVID shift (p=0.02); emotional (p<0.01) and quantitative (p<0.01) demands; regular caffeine intake (p=0.01); education level (p=0.005); regular exercise (p=0.003); regular fiber intake (p=0.08); and irregular menstrual cycles (p=0.007). In logistic regression only quantitative (p=0.003) and emotional (p=0.018) job demands were significant.
CONCLUSION
Results showed that the prevalence of PMS was high among Iranian nurses and was associated with quantitative and emotional job demands. We suggest further studies focusing on preventative and effective interventions to diminish the consequences of PMS in this population. We also suggest investigating the practical application of the findings of this study for healthcare professionals and policymakers.
PubMed: 38867710
DOI: 10.4274/jtgga.galenos.2024.2023-3-1 -
Best Practice & Research. Clinical... Jan 2024Defining, diagnosing and managing premenstrual disorders (PMDs) remains a challenge both for general practitioners and specialists. Yet these disorders are common and... (Review)
Review
Defining, diagnosing and managing premenstrual disorders (PMDs) remains a challenge both for general practitioners and specialists. Yet these disorders are common and can have an enormous impact on women. PMDD (premenstrual dysphoric disorder), one severe form of PMD, has a functional impact similar to major depression yet remains under-recognised and poorly treated. The aim of this chapter is to give some clarity to this area, provide a framework for non-specialists to work towards, and to stress the importance of MDT care for severe PMDs, including PMDD.
Topics: Female; Humans; Premenstrual Dysphoric Disorder; Luteal Phase
PubMed: 38182436
DOI: 10.1016/j.beem.2023.101858